Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company announced that it received approval from Health Canada to market its product, Diabasens® as a Natural Health Product to relieve cutaneous pain associated with diabetic neuropathy.
Diabetic neuropathy is a type of nerve damage that can occur in patients with diabetes. High blood sugar can injure nerves throughout your body. The condition most often damages nerves in legs and feet.
Diabasens® is a proprietary cream that relieves pain associated with diabetic neuropathy. The product is also designed with specific ingredients to increase blood flow into the legs and feet and increase nerve sensation.
The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
“We are very pleased to announce the Health Canada approval of our Diabasens® product in Canada,” said Dr. Bassam Damaj, the president and Chief Executive Officer of Innovus Pharma. “Diabasens is one of our top selling products in the United States, and we expect it to do very well in Canada and rise up to be a top performer there too.”
Damaj expects to launch the product in the very near future to provide Canadian diabetic patients with an effective product to relieve their diabetic neuropathy pain.
Diabasens® is the company’s eleventh product approved in Canada, including Zestra®, Zestra Glide® and Uxor™ (EjectDelay®) marketed by Orimed Pharma, UriVarx® through our partnership with Acerus Pharmaceuticals Corporation, and Vesele®, Apeaz®, Xyralid® Cream, ProstaGorx®, Xyralid® Suppositories and BH™ Testosterone Booster.
In addition, the company has two other products: PEVarx® and RecalMax® that have applications submitted and are being reviewed currently by Health Canada for potential approval.
For more information, view the full press release here.
Source:
- Innovus Pharma Announces the Approval of its Diabasens® Product in Canada Indicated to Relieve Cutaneous Pain Associated with Diabetic Neuropathy. (2019, March 1). Business Wire. Retrieved: https://www.businesswire.com/news/home/20190301005078/en